Pfizer's 2021 profits doubled to $22 bn on strong COVID vaccine sales
Pfizer forecast more than $50 billion in 2022 sales for its COVID-19 vaccine and therapeutic on Tuesday as the giant pharma company reported a more than doubling of annual profits on strong vaccine sales.